Perimeter Medical Imaging AI Inc reports two new commercial installations of its flagship Perimeter SSeries OCT system

Perimeter Medical Imaging AI Inc (TSX-V:PINK, OTC:PYNKF) has reported two new commercial installations of its flagship Perimeter SSeries OCT system, which were completed prior to year-end.

In a statement, Jeremy Sobotta, Perimeter’s chief executive officer commented: “I am excited by our considerable progress across the business, and we enter 2023 with growing momentum. Prior to year-end, we completed two additional commercial placements of our S-Series OCT technology, including successfully leveraging our existing presence within a major national healthcare system, resulting in the third commercial placement in this network.”

He added: “These two new placements at the end of 2022 were a great way to close a strong fourth quarter in which we doubled the total commercial installed base of our S-Series devices. Further, we believe the expansion within our existing customers’ networks indicates the value these early users are experiencing. These positive metrics are highly encouraging, and we remain focused on placing our innovative medical imaging technology in ORs across the US with the goal of improving patient outcomes and reducing overall healthcare costs.”

READ: Perimeter Medical Imaging AI reveals positive study results validating potential use of WF-OCT tech in head and neck surgeries.

Based in Toronto, Canada and Dallas, Texas, Perimeter Medical Imaging AI is a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address areas of high unmet medical need.

Available across the US, its Food & Drug Administration (FDA) cleared Perimeter S-Series OCT system provides real-time, cross-sectional visualization of excised tissues at the cellular level. The breakthrough-device-designated investigational Perimeter B-Series OCT with ImgAssist AI represents our next-generation artificial intelligence technology that is currently being evaluated in a pivotal clinical trial, with support from a grant of up to US$7.4 million awarded by the Cancer Prevention. and Research Institute of Texas.

Contact the author at [email protected]

Leave a Comment

Your email address will not be published. Required fields are marked *